Danaher (NYSE:DHR) shares ticked up today on second-quarter results that beat the consensus forecast.
The Washington, D.C.–based company posted profits of $1.7 billion, or $2.40 per share, on sales of $7.2 billion for the three months ended July 2, 2021, for a 95.5% bottom-line gain on sales growth of 36.3%.
Adjusted to exclude one-time items, earnings per share were $2.46, 41¢ ahead of Wall Street, where analysts were looking for sales of $6.7 billion.
“Broad-based strength across the portfolio helped us deliver over 30% core revenue growth and outstanding earnings per share growth and cash flow generation,” Danaher president & CEO Rainer M. Blair said in a news release. “We continued to make significant growth investments during the quarter, strengthening our organic growth trajectory and enhancing our portfolio with the announcement of our pending acquisition of Aldevron.
“We believe the combination of our leading portfolio and DBS-driven execution differentiates Danaher today and provides a strong foundation for sustainable, long-term outperformance.”
Danaher did not provide full-year guidance but said it anticipates third-quarter revenue growth in the mid-to-high teens percent range.
DHR shares were up 2.8% at $287.50 apiece in early-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was virtually level.